RxDoctor Payments Data

Donald Crabtree, DO

Pain Medicine · Hot Springs, ARNPI 1760649388

Payments from drug & device makers

What this record shows

Edwards Lifesciences accounts for 61.3% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2019 at $2,023 and has fallen 93.5% since, to $131 in 2025. That places this record below the midpoint for pain medicine clinicians in AR, where the typical reported total is $3,271.

$3,271in general payments, 2019–2025

Across 59 payments — averaging $55.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$2K
  • Boston Scientific$459
  • AbbVie$319
  • Collegium Pharmaceutical, Inc.$151
  • Phathom Pharmaceuticals, Inc.$125
  • Globus Medical$60
  • plus $152 from 6 others

What the payments were for

  • Travel & lodging$1,65651%
  • Food & beverage$1,61549%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,271 in reported general payments places this provider in the 50th percentile of 53 pain medicine providers in Arkansas.

See all pain medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$209,045
Medicare patients
219
Services billed
3,122

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen1,276$33,147
Xtampza ErOxycodone Myristate38$20,980
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen584$15,598
Hysingla ErHydrocodone Bitartrate14$12,844
BelbucaBuprenorphine Hcl13$10,799
Butorphanol Tartrate23$9,349
Morphine Sulfate ErMorphine Sulfate160$4,971
Naloxone Hcl45$3,203
Oxycodone Hcl162$3,016
Pregabalin138$2,345
Gabapentin128$2,231
Buprenorphine Hcl25$1,687
Fentanyl26$1,642
Morphine Sulfate58$1,412
Tizanidine Hcl97$1,135

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca$151$31,77851 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 53 pain medicine providers in Arkansas.

Other pain medicine in Hot Springs

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →